Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer which is negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), which nullifies existing endocrine therapies and targeted therapies. This evidence concerns the gene ERBB2 and breast carcinoma.